There are currently three 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists available in Australia. In this randomized, double-blind, parallel group study the prophylactic antiemetic effect of a single dose of tropisetron 2 mg, ondansetron 4 mg or dolasetron 12.5 mg was compared after major gynaecological surgery.
Postoperative nausea and vomiting (PONV) is a common problem after major abdominal gynaecological surgery, with a frequency as high as 91% 1 .
Many classes of antiemetic drugs are used to prevent PONV and the 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists are popular. Ondansetron, the original member of this drug group, effectively prevents PONV, with a number needed to treat to prevent vomiting of about five and a less pronounced antinausea effect [2] [3] [4] . It has a short elimination half-life and clinical efficacy may decline within six hours of surgery 1 . Tropisetron and dolasetron, drugs of similar class, are effective alternatives 5 with longer elimination half-lives (about eight hours) than ondansetron. A single dose of tropisetron appears to be effective against PONV for at least 18 hours 6, 7 and may reduce nausea for a longer period than ondansetron 8 . All these drugs are well tolerated and their side-effects are mild.
The cost-effectiveness of 5-HT 3 antagonists for PONV prophylaxis has been questioned 9, 10 , and is likely to depend on the underlying incidence of PONV in a given patient population as well as the cost and efficacy of the drug itself 11 . Dolasetron was found to be more cost-effective than ondansetron for preventing PONV after ear nose and throat surgery 12 , but comparison of the relative efficacy and costeffectiveness of different 5-HT 3 receptor antagonists for patients at high risk of PONV has not beenstudied. We therefore designed a double-blind, randomized controlled trial of the efficacy and relative costs associated with the use of prophylactic ondansetron, tropisetron and dolasetron during major abdominal gynaecological surgery under general anaesthesia.
METHODS
Following approval by the local Research and Ethics Committee and after obtaining written informed consent, 120 women scheduled for major open abdominal gynaecological or gynaecological oncological procedures were studied. Patients experiencing preoperative nausea, receiving medication with antiemetic activity or with contraindications to nonsteroidal anti-inflammatory medication or epidural anaesthesia were excluded from the study. In addition, women in whom an open procedure was not performed or who underwent unplanned bowel surgery were excluded.
All patients were premedicated with 20 mg temazepam one to two hours before transfer to theatre. A low thoracic (T9-T12) epidural was inserted prior to induction of anaesthesia and 6 to 10 ml of epidural ropivacaine 7.5 mg/ml with fentanyl 50 µg was administered. General anaesthesia was induced with fentanyl (maximum 200 µg) and thiopentone, endotracheal intubation facilitated with a nondepolarizing muscle relaxant of the anaesthetist's choice and anaesthesia maintained with isoflurane in nitrous oxide and oxygen.
Using a computer-derived randomization sequence in blinded envelopes, patients were assigned to one of three treatment groups: Group T: tropisetron 2 mg IV at induction. Group O: ondansetron 4 mg IV at induction. Group D: dolasetron 12.5 mg IV at the end of surgery.
The study drug, known only to the attending anaesthetist who took no part in the collection of subsequent data, was administered diluted with normal saline to a 4 ml volume. The timing of administration complied with the recommendation from the approved Product Information for each drug. Muscle relaxation was reversed with IV neostigmine (2.5 mg) and atropine (1.2 mg). Postoperative pain relief was provided by epidural infusion of ropivacaine 2 mg/ml with fentanyl 4 µg/ml at 6 to 12 ml/h and rectal diclofenac 100 mg was administered twice daily.
Patient characteristics of age, weight, history of previous PONV, history of motion sickness, stage of menstrual cycle, type and duration of surgery were noted. Assessments were made over six time periods; arrival in the recovery room to 30 minutes later and from then until 2, 6, 12, 18 and 24 hours. Antiemetic efficacy was determined by recording the incidence of emetic episodes and the requirement for rescue antiemetic medication during each observation period and cumulatively. An emetic episode was defined as vomiting or retching and constituted a separate episode if greater than five minutes apart. PONV experienced within the first 10 minutes of arrival in the recovery room was not treated, but thereafter was treated with prochlorperazine 12.5 mg IM initially. If the response to prochlorperazine was inadequate after one hour, droperidol 1 mg IV was given. In addition, the severity of nausea that was experienced at the time of assessment at the end of each study period was evaluated by a 100 mm visual analog score (VAS) in which 0 represented "not feeling sick at all" and 100 "feeling as sick as I could possibly feel". Using the same scale, VAS measurements were obtained for the worst degree of nausea experienced during each preceding time period and overall until 24 hours. VAS scales at 24 hours were used to assess patient satisfaction with the control of nausea and vomiting and with recovery from the operation, where 0 represented "not satisfied at all" and 100 represented "completely satisfied".
A "complete response" to prophylaxis was defined as no vomiting or rescue antiemetic drugs required throughout the study period. In addition, patients were asked to qualify how they felt using a rating of 0=well, no PONV; 1=not concerned by PONV; 2=PONV a problem; 3=PONV distressing. The volume of epidural solution infused during the study and times to first ambulation, oral fluid and oral diet intake were recorded.
For the cost-effectiveness analysis, direct costs for the management of emesis included the costs for "emesis clean-up" ($1), rescue anti-emetic dosing (prochlorperazine $0.80, droperidol $3.30) and the acquisition costs of an ampoule of the drug under investigation (ondansetron $17.70, tropisetron $14.05, dolasetron $19.50).
The sample size of 40 patients per group (total 120) was based on a desire to demonstrate a reduction in the incidence of vomiting of 50% in the first 24 hours by tropisetron or dolasetron compared with ondansetron (90% power and a significance level of 0.05). We considered this to be a clinically important reduction in incidence and we had observed a 75% incidence previously in a trial involving ondansetron 1 . The primary outcome and other frequency data were analysed as contingency tables using the chi-squared test. Continuously valued data such as patient age and weight were compared using t-tests and the analysis of variance. Ordinal data were analysed with the Kruskal-Wallis test on medians. A P value of 0.05 was considered significant.
RESULTS
A total of 120 patients were recruited into the study. Excluded from analysis were two patients from group O, one of whom did not have the procedure and one who was transferred to an intensive care unit postoperatively, precluding data collection. This left 118 patients (group T n=42; group O n=36; group D n=40).
Patients in each group were comparable in age, weight, history of PONV, history of motion sickness and stage of menstrual cycle. The duration and type of surgery and the volume of epidural solution administered postoperatively were similar (Table 1) .
There was no significant difference between the three groups in the incidence of vomiting during the first 24 hours, or the incidence of vomiting within each time period ( Table 2 ). The percentage of patients with a complete response to the study drug and the number of rescue antiemetic treatments did not significantly differ between groups ( Table 2 ).
There were no significant differences between groups with respect to the presence of nausea, the overall nausea score for the first 24 postoperative hours or for interval scores recorded at the end of each time period (Table 3 ). Patients who received tropisetron had a significantly lower "worst nausea score" during the period from 12 to 18 hours postoperatively (P=0.02), but not during any other time period. The percentage of patients who rated their PONV symptoms as "a problem" or "distressing" did not differ significantly (19, 26 and 20% of groups T, O and D respectively, P=0.75). The percentage who received antiemetic treatment during the study period (31, 42 and 30% of groups T, O and D respectively, P=0.50) and who received both prochlorperazine and droperidol (24, 33 and 25% of groups T, O and D respectively, P=0.60), was similar.
There was no difference between groups in the time taken after surgery to walk, start oral fluids or solid diet (Table 4 ). Satisfaction with control of PONV did not differ significantly (Table 3 ) and nor did satisfaction with recovery ( Table 4 ). No patients reported side-effects attributable to study medication.
The costs for each group were calculated using the total cost divided by number of patients in the group. The total cost was estimated by summing the acquisition cost of study drug and rescue antiemetic and the cost associated with clean up of emesis. In group T this included 50 emetic episodes plus 42 doses of prochlorperazine and 14 doses of droperidol; in group O, 56 emetic episodes plus 40 prochlorperazine and 16 droperidol doses; and in group D, 54 episodes plus 42 prochlorperazine and 18 droperidol doses. The calculated cost per patient was $17.15, $23.40 and $21.40 for tropisetron, ondansetron and dolasetron respectively.
DISCUSSION
In this clinical trial we found no significant difference in the efficacy, during the first 24 hours after major gynaecological surgery, of a prophylactic single intravenous injection of tropisetron, ondansetron or dolasetron. The incidence and severity of vomiting; of nausea; the need for rescue antiemetic treatment Values are mean (standard deviation) for age and weight or number (percentage), except for median (interquartile range) for surgical duration and volume of epidural solution. There were no significant differences between groups for any variables. and number of treatments; and the patient assessment of control of PONV, were all similar. Failure of prophylaxis was frequent with each drug. A costminimization analysis found that cost was principally determined by the acquisition cost of the drug, and based on the recommended cost price at the time, cost-saving was achieved using tropisetron. We believe the influence of confounding factors was minimal in this study, given groups were balanced for patients with a past history of PONV, for the stage of the menstrual cycle, and for a history of smoking. Prophylactic administration of antiemetics can be justified in those at very high risk of PONV 4,10 and women having major gynaecological surgery repre-sent such a group 1 . The 5-HT 3 antagonists are very popular prophylactic antiemetics, with a greater effect on vomiting than nausea 2,3,5 . Emesis that follows a rise in local concentration of 5-HT 3 at receptors, especially in vagal afferent terminals in the gut mucosa and brainstem centres where receptor density is high, can be prevented by antagonists. Prophylactic ondansetron is only marginally more effective than treatment 9 , but becomes cost-effective if the incidence of PONV is greater than 30% 11 .
Quantitative systematic reviews show that ondansetron 4 mg is an effective prophylactic dose, with a number needed to treat to stop vomiting compared with placebo of 5 to 6 2,3 . This means that for every 5 to 6 patients given ondansetron, one who would have otherwise have vomited will be emesis free. A dose of 8 mg has been said to be more effective 2 , although direct analysis of combined data for 4 and 8 mg doses shows that the results are not significantly different 11 and subgroup analysis of those with a past history of PONV does not show altered effectiveness 13 . The 5-HT 3 antagonists are also more effective than other antiemetics 5, 14 , with one meta-analysis (assuming equal efficacy of all members of this class) finding a reduction in the odds of both vomiting and of PONV, compared with droperidol and metoclopramide, after gynaecological surgery 5 . A limited number of dual comparative trials 8, 15, 16 suggest there are no clinical advantages associated with any one particular 5-HT 3 antagonist. Our comparison of three such drugs of this class (granisetron was not available to us) supports this conclusion. We had anticipated that both tropisetron and dolasetron might prove more effective after the early postoperative period. The pharmacokinetics of tropisetron and dolasetron differ from those of ondansetron, with both having a longer elimination half-life and being recommended for twice daily rather than six hourly administration. The half-life of intravenous dolasetron is four to eight hours and of tropisetron eight hours in extensive metabolizers (30 hours in poor metabolizers) compared with ondansetron three to four hours [17] [18] [19] . Our failure to find a more prolonged effect may have been due to the high incidence of early PONV in all groups and the subsequent activity of rescue antiemetics, or because there are no differences in duration of effect. In a small study of low power, Naguib and colleagues found that only ondansetron, and not granisetron or tropisetron, was more effective than metoclopramide and placebo after laparoscopic cholecystectomy 15 . Kortilla and coworkers found intravenous dolasetron 50 mg and ondansetron 4 mg were of similar efficacy in a large unselected surgical population 16 . Tropisetron 2 mg and ondansetron 4 mg have similar efficacy after abdominal surgery 20 . The only study to find a difference compared tropisetron 5 mg with ondansetron 4 mg at induction of anaesthesia for major gynaecological surgery and found lower eight to sixteen hour nausea scores after tropisetron 8 . An outcome we found consistent with the above was significantly less severe nausea between 12 and 18 hours after surgery associated with tropisetron, although this may have been a chance finding. If a true difference exists between the 5-HT 3 antagonists, its magnitude does not appear clinically relevant.
It is arguable whether the approved doses we administered were optimal. Tramer and colleagues recommended ondansetron 8 mg IV for prophylaxis in high-risk settings 2 . Figueredo and Canosa 13 found 8 mg was numerically more effective than 4 mg for patients with a past history of PONV compared to placebo for an outcome of no vomiting (odds ratio (95% confidence interval)) 4.21 (2.66-6.66) versus 2.40 (1.77-3.26). However, there was no difference in early or late vomiting or nausea in a direct comparison of these doses using the same data as analysed by Tramer and co-workers, who compared each dose against placebo 11 . The optimum dose of tropisetron is also uncertain, but 2 mg shows similar efficacy to 5 mg for up to 24 hours when the risk of PONV is moderate 15, 21 . When the risk of PONV is very high (over 80%), 5 mg may confer better efficacy after six hours 7 . Dolasetron 12.5 mg is recommended based on dose response studies and pooled analysis of three large randomized trials 22, 23 . Complete response in gynaecological patients may be related to dose, but 25 mg has no greater efficacy than 12.5 mg 24 .
It is also possible that the timing of administration of these drugs was not ideal. It is not known if the timing of tropisetron or dolasetron administration influences efficacy. The approved timing of ondansetron, at induction of anaesthesia, has been questioned because less frequent and severe emesis and better patient satisfaction were found when it was administered at the end of surgery 25, 26 .
The main side-effects of the 5-HT 3 antagonists are headache, elevated liver enzymes, and constipation and a flushing sensation in the head or epigastrium. It is estimated that three in 100 patients receiving ondansetron will have headache or elevated liver enzymes they would not otherwise have had 2 . However, the incidence of headache is low (less than 10%) and is not significantly different to placebo (odds ratio 1.16 CI 0.93-1.46) 3 . The safety profiles of dolasetron and ondansetron are similar 16 and dolasetron is well tolerated intravenously 22, 24 . The 5-HT 3 antagonists rarely (less than 1 in 1000) cause extrapyramidal reactions such as chorea, oculogyric crisis or dystonia 27 or psychiatric disturbance (such as panic attack and depression). These are possible even after a single intravenous dose, possibly because the serotonergic system has a regulatory role on central dopamine 2 -receptor motor inhibitory activity in the basal ganglia and related limbic system nuclei.
When the risk of PONV is high, a combination of drugs with different antiemetic activities is recommended 4, 10 . Although few studies have addressed combination therapy, women receiving prophylactic droperidol and ondansetron are significantly more likely to be free of PONV than those receiving either drug alone 28 . The 5-HT 3 antagonists are less costeffective than droperidol in females having ambulatory gynaecological surgery, where the efficacy of these drugs is similar 29 . Similar analyses have not been performed for major gynaecological surgery, where ondansetron is of equivalent 30 or slightly greater efficacy 1 . Increased value of anaesthetic care can be obtained by achieving the same outcome at lower cost or a better outcome at a higher cost. Our results, showing similar efficacy and no clinically relevant side-effects of the 5-HT 3 antagonists, allowed us to perform a cost-minimization analysis. It was not necessary to include costs associated with management of drug side-effects or associated with differences that must be accounted for in a costeffectiveness analysis, such as variable costs (personnel); fixed costs (duration of hospital stay); or indirect costs (loss of productivity).
When equally effective doses of dolasetron and ondansetron were compared for otolaryngological surgery, the cost comparison favoured dolasetron 12.5 mg, because of its lower purchase cost in that study 12 . The acquisition cost of a 5-HT 3 antagonist is often negotiated between the manufacturer and the retailer. Thus, because the drugs appear clinically indistinguishable, we would recommend a cost containment strategy based on choice of the drug that is currently least expensive in that setting.
